The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management
Issued Date
2024-01-01
Resource Type
ISSN
22285881
eISSN
22517308
Scopus ID
2-s2.0-85200628585
Journal Title
Advanced Pharmaceutical Bulletin
Volume
14
Issue
2
Start Page
314
End Page
330
Rights Holder(s)
SCOPUS
Bibliographic Citation
Advanced Pharmaceutical Bulletin Vol.14 No.2 (2024) , 314-330
Suggested Citation
Anurogo D., Luthfiana D., Anripa N., Fauziah A.I., Soleha M., Rahmah L., Ratnawati H., Wargasetia T.L., Pratiwi S.E., Siregar R.N., Sholichah R.N., Maulana M.S., Ikrar T., Chang Y.H., Qiu J.T. The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management. Advanced Pharmaceutical Bulletin Vol.14 No.2 (2024) , 314-330. 330. doi:10.34172/apb.2024.034 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/100460
Title
The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management
Author's Affiliation
Badan Riset dan Inovasi Nasional
College of Medicine
School of Medicine
Universitas Malahayati
Indonesia Defense University
Universitas Muhammadiyah Surabaya
Universitas Muhammadiyah Makassar
Universitas Kristen Maranatha
Universitas Tanjungpura
Universitas Gadjah Mada
Tehran University of Medical Sciences, School of Medicine
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Kaohsiung Medical University
Taipei Medical University Hospital
Dumoga University
East Jakarta
Community Health Center (Puskesmas)
The Indonesian Medical Council (KKI)
Indonesian Institute of Bioinformatics (INBIO)
Ltd.
AIVITA Biomedical, Inc.
At-Large
College of Medicine
School of Medicine
Universitas Malahayati
Indonesia Defense University
Universitas Muhammadiyah Surabaya
Universitas Muhammadiyah Makassar
Universitas Kristen Maranatha
Universitas Tanjungpura
Universitas Gadjah Mada
Tehran University of Medical Sciences, School of Medicine
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Kaohsiung Medical University
Taipei Medical University Hospital
Dumoga University
East Jakarta
Community Health Center (Puskesmas)
The Indonesian Medical Council (KKI)
Indonesian Institute of Bioinformatics (INBIO)
Ltd.
AIVITA Biomedical, Inc.
At-Large
Corresponding Author(s)
Other Contributor(s)
Abstract
Purpose: Lymphoma, the most predominant neoplastic disorder, is divided into Hodgkin and Non-Hodgkin Lymphoma classifications. Immunotherapeutic modalities have emerged as essential methodologies in combating lymphoid malignancies. Chimeric Antigen Receptor (CAR) T cells exhibit promising responses in chemotherapy-resistant B-cell non-Hodgkin lymphoma cases. Methods: This comprehensive review delineates the advancement of CAR-T cell therapy as an immunotherapeutic instrument, the selection of lymphoma antigens for CAR-T cell targeting, and the conceptualization, synthesis, and deployment of CAR-T cells. Furthermore, it encompasses the advantages and disadvantages of CAR-T cell therapy and the prospective horizons of CAR-T cells from a computational research perspective. In order to improve the design and functionality of artificial CARs, there is a need for TCR recognition investigation, followed by the implementation of a quality surveillance methodology. Results: Various lymphoma antigens are amenable to CAR-T cell targeting, such as CD19, CD20, CD22, CD30, the kappa light chain, and ROR1. A notable merit of CAR-T cell therapy is the augmentation of the immune system’s capacity to generate tumoricidal activity in patients exhibiting chemotherapy-resistant lymphoma. Nevertheless, it also introduces manufacturing impediments that are laborious, technologically demanding, and financially burdensome. Physical, physicochemical, and physiological limitations further exacerbate the challenge of treating solid neoplasms with CAR-T cells. Conclusion: While the efficacy and safety of CAR-T cell immunotherapy remain subjects of fervent investigation, the promise of this cutting-edge technology offers valuable insights for the future evolution of lymphoma treatment management approaches. Moreover, CAR-T cell therapies potentially benefit patients, motivating regulatory bodies to foster international collaboration.
